Exchange: NASDAQ·Updated 01:36 PM EDT
News
all
press releases
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.
Stocktwits
More News
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
Zacks
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.
Stocktwits
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Zacks
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...
PR Newswire
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead...
Yahoo! Finance: News
Theravance Stock Down 3% After Zymeworks Announces Buyout
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zacks
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.read more...
Benzinga
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders
Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years.
Stocktwits

Advertisement|Remove ads.